CUE
Cue Biopharma, Inc.
$33.39
+0.90 (+2.75%)
At close · Jul 7
Market Cap
$135.09M
Shares
4,045,701
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$27.47M
+195.7%
FY2025
Net Income
-$26.6M
+34.6%
FY2025
Operating Margin
-96.67%
+350.2pp
FY2025
Diluted EPS
-$8.40
+61.1%
FY2025
Operating Cash Flow
-$21.69M
+40.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $32.73M | $27.47M | $9.29M | $5.49M | $1.25M | $14.94M | $3.15M | $3.46M | $1.14M | — | |
| -$233K | -$357K | -$796K | -$1.25M | -$713K | $0 | — | — | — | — | |
| — | — | — | $0 | $277K | $0 | — | — | — | — | |
| $36.09M | $37.74M | $36.3M | $40.8M | $38.58M | $41.35M | $33.55M | $27.49M | $28.54M | $18.9M | |
| $16.22M | $16.24M | $14.59M | $16.68M | $16.17M | $17.31M | $14.65M | $12.74M | $11.3M | $4.33M | |
| — | — | — | — | — | — | $11.67K | $11.67K | — | — | |
| — | $958K | $397K | $556K | $922K | $1.26M | $1.06M | $810.78K | $760.01K | — | |
| $52.34M | $54.02M | $50.79M | $57.64M | $54.47M | $58.65M | $48.2M | $40.23M | $39.84M | $23.23M | |
| -$19.61M | -$26.55M | -$41.5M | -$52.15M | -$53.23M | -$43.71M | -$45.04M | -$36.77M | -$38.7M | -$23.23M | |
| — | -96.67% | -446.86% | -949.89% | -4275.1% | -292.56% | -1427.96% | -1063.21% | -3386.71% | — | |
| — | -$25.59M | -$41.1M | -$51.59M | -$52.3M | -$42.45M | -$43.99M | -$35.96M | -$37.94M | — | |
| — | $100K | $100K | $100K | $109K | — | — | — | — | — | |
| $583K | $450K | $826K | $1.42M | $215K | $45.9K | $463.91K | $482.79K | $541.35K | $35 | |
| — | — | — | — | -$53.01M | -$43.67M | -$44.58M | -$36.29M | -$38.16M | -$23.23M | |
| — | $500K | $0 | — | $0 | $495K | $206.25K | $412.5K | $825K | — | |
| -$19.52M | -$26.6M | -$40.67M | -$50.73M | -$53.01M | -$44.16M | -$44.78M | -$36.7M | -$38.98M | -$23.23M | |
| — | -96.85% | -437.97% | -924.1% | -4257.83% | -295.56% | -1419.79% | -1061.18% | -3411.53% | — | |
| -$37.68M | — | -$40.67M | -$50.64M | -$53.11M | -$44.17M | -$44.77M | -$36.7M | -$38.99M | -$23.23M | |
| USD/shares | — | -$8.40 | -$21.60 | -$33.30 | -$44.70 | -$42.30 | — | — | — | — |
| USD/shares | — | -$8.40 | -$21.60 | -$33.30 | -$44.70 | -$42.30 | — | — | — | — |
| shares | — | 3.16M | 1.88M | 1.53M | 1.19M | 1.04M | 956.29K | 734.73K | 671.14K | 357.75K |
| shares | — | 3.16M | 1.88M | 1.53M | 1.19M | 1.04M | 956.29K | 734.73K | 671.14K | 357.75K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2019–FY2023: $1.31M in buybacks.